VIA
FPRX

Vident Investment Advisory’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Vident Investment Advisory’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-133,272
Closed -$1.85M – 966
2018
Q3 		$1.85M Sell
133,272
-8,882
-6% -$132K 0.07% 343
2018
Q2 		$2.25M Buy
142,154
+60,608
+74% +$1.06M 0.09% 307
2018
Q1 		$1.41M Buy
81,546
+21,779
+36% +$425K 0.06% 349
2017
Q4 		$1.31M Buy
59,767
+18,994
+47% +$611K 0.06% 332
2017
Q3 		$1.67M Sell
40,773
-46,836
-53% -$1.47M 0.09% 298
2017
Q2 		$2.64M Buy
87,609
+22,940
+35% +$716K 0.22% 138
2017
Q1 		$2.34M Sell
64,669
-872
-1% -$38.4K 0.23% 195
2016
Q4 		$3.28M Sell
65,541
-9
-0% -$473 0.4% 45
2016
Q3 		$3.44M Buy
65,550
+48,935
+295% +$2.34M 0.46% 24
2016
Q2 		$687K Sell
16,615
-18,681
-53% -$813K 0.1% 323
2016
Q1 		$1.43K Buy
35,296
+16,412
+87% +$564K 0.09% 338
2015
Q4 		$784K Buy
+18,884
New +$633K 0.1% 334

Other funds holding FPRX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vident Investment Advisory's FPRX Position: Q4 2018 in Review

Vident Investment Advisory sold out of Five Prime Therapeutics, Inc. (FPRX) in Q4 2018, closing a stake of 133,272 shares — an estimated $1.85M sold.

Vident Investment Advisory first reported a position in FPRX in Q4 2015 and held it in 12 quarters. The position peaked at $3.44M in Q3 2016. 116 funds tracked by Wall St. Rank hold FPRX as of Q4 2018.

  • Vident Investment Advisory reported no remaining Five Prime Therapeutics, Inc. position as of Q4 2018 after selling out during the quarter.
  • Vident Investment Advisory sold 133,272 Five Prime Therapeutics, Inc. shares in Q4 2018, an estimated $1.85M.
  • Vident Investment Advisory first reported a position in Five Prime Therapeutics, Inc. in Q4 2015 and held it in 12 quarters.
  • Vident Investment Advisory's Five Prime Therapeutics, Inc. position peaked at $3.44M in Q3 2016.
  • 116 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q4 2018.

Based on Vident Investment Advisory's 13F filing for Q4 2018, filed 14 Feb 2019.